This protocol covers the clinical scenario where standard first-line Giardiasis therapy has not produced the expected response — persistent infection or relapse after the initial treatment course.
First-line management with agents such as metronidazole, tinidazole, ornidazole, quinacrine, furazolidone, or albendazole targets parasite clearance from the stool within 3–5 days and symptom resolution within 5–7 days. This protocol applies when those goals were not reached — parasites persist in the stool or symptoms continue beyond the expected window, or infection has relapsed after an initial response.
Refractory or relapsing Giardiasis calls for moving beyond the initial drug class. The approach involves switching to an anti-Giardia agent from a different drug class, or deploying a combination regimen — the specific regimen composition, options, and duration are detailed in the full protocol.
Eradication of infection, confirmed by clearance of Giardia from the stool.
DOI: 10.1128/CMR.14.1.114–128.2001
If resistance or relapse has occurred, treatment with a drug of a different class or with a combination of a nitroimidazole and quinacrine for at least 2 weeks should eradicate infection.
Combination regimens using metronidazole-albendazole, metronidazole-quinacrine, or other active drugs or giving a nitroimidazole plus quinacrine for courses of at least 2 weeks have proven successful against refractory infection.
View source ↗